Physician profile
Jay P White
NPI 1720054042
$3,938.05
in general payments reported to CMS, 2019-2025
40 companies · $851 in 2025
The $851 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $89.80 · 2021: $123 · 2022: $944 · 2023: $639 · 2024: $816 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $527.56 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $441.41 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $379.11 | 2023-2024 | Myfembree, Gemtesa |
| Abbvie INC. | $321.71 | 2019-2023 | Orilissa, Lo Loestrin Fe, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $227.51 | 2022-2025 | |
| Aspira Women'S Health INC | $176.99 | 2020-2022 | |
| Daiichi Sankyo INC. | $158.80 | 2019-2024 | Injectafer |
| Pfizer INC. | $158.24 | 2022-2025 | |
| Exeltis, USA INC. | $148.12 | 2022-2025 | Slynd |
| Myovant Sciences INC. | $141.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $118.70 | 2022 | |
| Organon LLC | $116.46 | 2022-2024 | Nexplanon |
| Therapeuticsmd, INC. | $114.23 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $97.14 | 2025 | Qelbree |
| Mayne Pharma Commercial LLC | $87.30 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.